535 results on '"Lentzsch P."'
Search Results
2. High-dose melphalan-autologous hematopoietic cell transplantation in systemic AL amyloidosis following daratumumab-based frontline therapy
- Author
-
Mellgard, George S., Bhutani, Divaya, Mapara, Markus Y., Maurer, Mathew S., Radhakrishnan, Jai, Lentzsch, Suzanne, and Chakraborty, Rajshekhar
- Published
- 2024
- Full Text
- View/download PDF
3. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
- Author
-
White, Darrell, Schiller, Gary, Madan, Sumit, Lentzsch, Suzanne, Chubar, Evgeni, Lavi, Noa, Van Domelen, Dane, Bentur, Ohad, and Baljevic, Muhamed
- Subjects
once weekly dose ,optimal triplet combination ,pomalidomide ,relapsed/refractory multiple myeloma ,selinexor - Abstract
OBJECTIVE: To identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd). METHODS: An analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 and SPd-40, respectively) given to patients with relapsed/refractory multiple myeloma (RRMM) in the STOMP (NCT02343042) and XPORT-MM-028 (NCT04414475) trials. RESULTS: Twenty-eight patients (60.7% males, median age 67.5 years) and 20 patients (35.0% males, median age 65.5 years) were analyzed in the SPd-40 and SPd-60 cohorts, respectively. Overall response rate was 50% (95% confidence interval [CI] 30.6-69.4%) and 65% (95% CI 40.8-84.6%), respectively. Very good partial response or better was reported in 28.6% (95% CI 13.2-48.7%) and 30.0% (95% CI 11.9-54.3%) of patients, respectively. Among 27 responders in both cohorts, the 12-month sustained response rate was 83.3% (95% CI 64.7-100.0%) for SPd-40 and 28.1% (95% CI 8.9-88.8%) for SPd-60. Median progression-free survival was 18.4 months (95% CI 6.5 months, not evaluable [NE]) and 9.5 months (95% CI 7.6 months-NE) for SPd-40 and SPd-60, respectively. Twenty-four-month survival rates were 64.2% (95% CI 47.7-86.3%) for SPd-40 and 51.1% (95% CI 29.9-87.5%) for SPd-60. Treatment-emergent adverse events (TEAEs) included neutropenia (all grades: SPd-40 64.3% versus SPd-60 75.0%), anemia (46.4% versus 65.0%), thrombocytopenia (42.9% versus 45.0%), fatigue (46.4% versus 75.0%), nausea (32.1% versus 70.0%) and diarrhea (28.6% versus 35.0%). CONCLUSION: The all-oral combination of SPd exhibited preliminary signs of efficacy and was generally tolerable in patients with RRMM. The overall risk-benefit profile favored the SPd-40 regimen.
- Published
- 2024
4. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
- Author
-
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, Aniko Szabo, Carolina Schinke, Binod Dhakal, Suzanne Lentzsch, Anita D’Souza, Ghulam Rehman Mohyuddin, Kelley Julian, Shonali Midha, Patrick Costello, Martin Kaiser, Melissa Ng Liet Hing, Simon J. Harrison, Edward R. Scheffer Cliff, and Meera Mohan
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2024
- Full Text
- View/download PDF
5. Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
- Author
-
Chakraborty, Rajshekhar, Cheruvalath, Heloise, Patwari, Anannya, Szabo, Aniko, Schinke, Carolina, Dhakal, Binod, Lentzsch, Suzanne, D’Souza, Anita, Mohyuddin, Ghulam Rehman, Julian, Kelley, Midha, Shonali, Costello, Patrick, Kaiser, Martin, Hing, Melissa Ng Liet, Harrison, Simon J., Cliff, Edward R. Scheffer, and Mohan, Meera
- Published
- 2024
- Full Text
- View/download PDF
6. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Author
-
Mohan, Meera, Monge, Jorge, Shah, Nishi, Luan, Danny, Forsberg, Mark, Bhatlapenumarthi, Vineel, Balev, Metodi, Patwari, Anannya, Cheruvalath, Heloise, Bhutani, Divaya, Thanendrarajan, Sharmilan, Dhakal, Binod, Zangari, Maurizio, Al-Hadidi, Samer, Cooper, Dennis, Lentzsch, Suzanne, van Rhee, Frits, D’Souza, Anita, Szabo, Aniko, Schinke, Carolina, and Chakraborty, Rajshekhar
- Published
- 2024
- Full Text
- View/download PDF
7. Dodecamer assembly of a metazoan AAA+ chaperone couples substrate extraction to refolding
- Author
-
Gupta, Arpit, Lentzsch, Alfred M, Siegel, Alex, Yu, Zanlin, Chio, Un Seng, Cheng, Yifan, and Shan, Shu-ou
- Subjects
1.1 Normal biological development and functioning ,Underpinning research ,Generic health relevance ,Animals ,Humans ,Molecular Chaperones ,Protein Refolding - Abstract
Ring-forming AAA+ chaperones solubilize protein aggregates and protect organisms from proteostatic stress. In metazoans, the AAA+ chaperone Skd3 in the mitochondrial intermembrane space (IMS) is critical for human health and efficiently refolds aggregated proteins, but its underlying mechanism is poorly understood. Here, we show that Skd3 harbors both disaggregase and protein refolding activities enabled by distinct assembly states. High-resolution structures of Skd3 hexamers in distinct conformations capture ratchet-like motions that mediate substrate extraction. Unlike previously described disaggregases, Skd3 hexamers further assemble into dodecameric cages in which solubilized substrate proteins can attain near-native states. Skd3 mutants defective in dodecamer assembly retain disaggregase activity but are impaired in client refolding, linking the disaggregase and refolding activities to the hexameric and dodecameric states of Skd3, respectively. We suggest that Skd3 is a combined disaggregase and foldase, and this property is particularly suited to meet the complex proteostatic demands in the mitochondrial IMS.
- Published
- 2023
8. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
- Author
-
Meera Mohan, Jorge Monge, Nishi Shah, Danny Luan, Mark Forsberg, Vineel Bhatlapenumarthi, Metodi Balev, Anannya Patwari, Heloise Cheruvalath, Divaya Bhutani, Sharmilan Thanendrarajan, Binod Dhakal, Maurizio Zangari, Samer Al-Hadidi, Dennis Cooper, Suzanne Lentzsch, Frits van Rhee, Anita D’Souza, Aniko Szabo, Carolina Schinke, and Rajshekhar Chakraborty
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract The objective of our study was to report real-world data on the safety and efficacy of standard-of-care teclistamab in patients with relapsed/refractory multiple myeloma (MM). This is a multi-institutional retrospective cohort study and included all consecutive patients that received at least one dose of teclistamab up until August 2023. One hundred and ten patients were included, of whom, 86% had triple-class refractory disease, 76% penta-refractory disease, and 35% had prior exposure to B-cell maturation antigen (BCMA)-targeting therapies. The overall response rate (ORR) in our cohort was 62%, with a ≥ very good partial remission (VGPR) rate of 51%. The ORR in patients with and without prior BCMA-targeted therapies was 54% vs 67%, respectively (p = 0.23). At a median follow-up of 3.5 months (range, 0.39–10.92), the estimated 3 month and 6 month progression free survival (PFS) was 57% (95% CI, 48%, 68%) and 52% (95% CI, 42%, 64%) respectively. The incidence of cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) was 56% and 11% respectively, with grade ≥3 CRS and ICANS noted in 3.5% and 4.6% of patients respectively. 78 unique infections were diagnosed in 44 patients, with the incidence of all-grade and grade ≥3 infections being 40% vs 26% respectively. Primary prophylaxis with intravenous immunoglobulin (IVIG) was associated with a significantly lower infection risk on multivariate analysis (Hazard ratio [HR] 0.33; 95% CI 0.17, 0.64; p = 0.001).
- Published
- 2024
- Full Text
- View/download PDF
9. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment.
- Author
-
Baljevic, Muhamed, Gasparetto, Cristina, Schiller, Gary, Tuchman, Sascha, Callander, Natalie, Lentzsch, Suzanne, Monge, Jorge, Kotb, Rami, Bahlis, Nizar, White, Darrell, Chen, Christine, Sutherland, Heather, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher, Bensinger, William, Biran, Noa, DeCastro, Andrew, Van Domelen, Dane, Zhang, Chris, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, Bentur, Ohad, and Lipe, Brea
- Subjects
anti‐BCMA ,multiple myeloma ,selinexor - Abstract
There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.
- Published
- 2022
10. Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
- Author
-
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, and Muhamed Baljevic
- Subjects
selinexor ,once weekly dose ,optimal triplet combination ,relapsed/refractory multiple myeloma ,pomalidomide ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 and SPd-40, respectively) given to patients with relapsed/refractory multiple myeloma (RRMM) in the STOMP (NCT02343042) and XPORT-MM-028 (NCT04414475) trials.ResultsTwenty-eight patients (60.7% males, median age 67.5 years) and 20 patients (35.0% males, median age 65.5 years) were analyzed in the SPd-40 and SPd-60 cohorts, respectively. Overall response rate was 50% (95% confidence interval [CI] 30.6-69.4%) and 65% (95% CI 40.8-84.6%), respectively. Very good partial response or better was reported in 28.6% (95% CI 13.2-48.7%) and 30.0% (95% CI 11.9-54.3%) of patients, respectively. Among 27 responders in both cohorts, the 12-month sustained response rate was 83.3% (95% CI 64.7-100.0%) for SPd-40 and 28.1% (95% CI 8.9-88.8%) for SPd-60. Median progression-free survival was 18.4 months (95% CI 6.5 months, not evaluable [NE]) and 9.5 months (95% CI 7.6 months-NE) for SPd-40 and SPd-60, respectively. Twenty-four-month survival rates were 64.2% (95% CI 47.7-86.3%) for SPd-40 and 51.1% (95% CI 29.9-87.5%) for SPd-60. Treatment-emergent adverse events (TEAEs) included neutropenia (all grades: SPd-40 64.3% versus SPd-60 75.0%), anemia (46.4% versus 65.0%), thrombocytopenia (42.9% versus 45.0%), fatigue (46.4% versus 75.0%), nausea (32.1% versus 70.0%) and diarrhea (28.6% versus 35.0%).ConclusionThe all-oral combination of SPd exhibited preliminary signs of efficacy and was generally tolerable in patients with RRMM. The overall risk-benefit profile favored the SPd-40 regimen.
- Published
- 2024
- Full Text
- View/download PDF
11. Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL Amyloidosis
- Author
-
Hughes MS and Lentzsch S
- Subjects
plasma cell dyscrasia ,daratumumab ,al amyloidosis ,adverse events ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Michael Sang Hughes, Suzanne Lentzsch Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY, USACorrespondence: Suzanne Lentzsch, Department of Hematology-Oncology, Columbia University Irving Medical Center, MH-6GN 435, 161 Fort Washington Ave, New York, NY, 10032, USA, Tel +1 212-305-5098, Email sl3440@cumc.columbia.eduIntroduction: Systemic AL amyloidosis, a plasma cell dyscrasia, is characterized by the production of misfolded immunoglobulin light chain. These misfolded proteins aggregate into amyloid fibrils and deposit throughout the body, resulting in widespread organ dysfunction and ultimately death. Achieving rapid and maximal elimination of the plasma cell clone is crucial to long-term survival. Daratumumab, an anti-CD38 monoclonal antibody delivered intravenously, has been swiftly incorporated into standard first-line treatment regimens. A novel formulation of daratumumab has been developed that can be injected subcutaneously.Areas Covered: As a retrospective qualitative review of prior publications involving daratumumab, this work briefly summarizes the existing data regarding the safety and efficacy of subcutaneous (SC) daratumumab, compared to intravenous (IV) daratumumab. SC daratumumab appears to deliver the same disease benefit as IV daratumumab to patients with decreased infusion-related reactions (IRRs), decreased time for administration, and similar rates of adverse events (AEs) intrinsically related to daratumumab.Expert Opinion: SC daratumumab is preferred over IV daratumumab, but the clinical situation ultimately should determine route of administration. Further investigation into cost-effectiveness benefit is warranted. Keywords: plasma cell dyscrasia, daratumumab, AL amyloidosis, adverse events, AE
- Published
- 2023
12. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- Author
-
Rajshekhar Chakraborty, Divaya Bhutani, Mathew S. Maurer, Meera Mohan, Suzanne Lentzsch, and Anita D’Souza
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2023
- Full Text
- View/download PDF
13. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosis
- Author
-
Chakraborty, Rajshekhar, Bhutani, Divaya, Maurer, Mathew S., Mohan, Meera, Lentzsch, Suzanne, and D’Souza, Anita
- Published
- 2023
- Full Text
- View/download PDF
14. The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
- Author
-
Fu, Jing, Li, Shirong, Ma, Huihui, Yang, Jun, Pagnotti, Gabriel M., Brown, Lewis M., Weiss, Stephen J., Mapara, Markus Y., and Lentzsch, Suzanne
- Published
- 2023
- Full Text
- View/download PDF
15. Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma
- Author
-
George Mellgard, Molly Gilligan, Edward R. Scheffer Cliff, Divaya Bhutani, Ghulam R. Mohyuddin, Andrew Eisenberger, Suzanne Lentzsch, and Rajshekhar Chakraborty
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2024
- Full Text
- View/download PDF
16. Lung Transplantation for Pulmonary AL Amyloidosis
- Author
-
Matthew I. Ehrlich, MD, Michael S. Hughes, MD, Brian W. Labadie, MD, Markus D. Siegelin, MD, Frank D’Ovidio, MD, PhD, Rachel Bijou, MD, Suzanne Lentzsch, MD, PhD, and Selim M. Arcasoy, MD, MPH
- Subjects
Surgery ,RD1-811 - Published
- 2024
- Full Text
- View/download PDF
17. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients
- Author
-
Gasparetto, Cristina, Schiller, Gary J, Tuchman, Sascha A, Callander, Natalie S, Baljevic, Muhamed, Lentzsch, Suzanne, Rossi, Adriana C, Kotb, Rami, White, Darrell, Bahlis, Nizar J, Chen, Christine I, Sutherland, Heather J, Madan, Sumit, LeBlanc, Richard, Sebag, Michael, Venner, Christopher P, Bensinger, William I, Biran, Noa, Ammu, Sonia, Ben-Shahar, Osnat, DeCastro, Andrew, Van Domelen, Dane, Zhou, Tianjun, Zhang, Chris, Bentur, Ohad S, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Lipe, Brea
- Subjects
Biomedical and Clinical Sciences ,Cardiovascular Medicine and Haematology ,Oncology and Carcinogenesis ,Rare Diseases ,Cancer ,Hematology ,Clinical Research ,Evaluation of treatments and therapeutic interventions ,6.1 Pharmaceuticals ,Adult ,Aged ,Antineoplastic Combined Chemotherapy Protocols ,Dexamethasone ,Drug Administration Schedule ,Female ,Humans ,Hydrazines ,Male ,Maximum Tolerated Dose ,Middle Aged ,Multiple Myeloma ,Oligopeptides ,Survival Analysis ,Translocation ,Genetic ,Treatment Outcome ,Triazoles ,Public Health and Health Services ,Oncology & Carcinogenesis ,Oncology and carcinogenesis - Abstract
BackgroundProteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM).MethodsThe safety, efficacy, maximum-tolerated dose (MTD) and recommended phase 2 dose (RP2D) of selinexor (80 or 100 mg) + carfilzomib (56 or 70 mg/m2) + dexamethasone (40 mg) (XKd) once weekly (QW) was evaluated in patients with relapsed refractory MM (RRMM) not refractory to carfilzomib.ResultsThirty-two patients, median prior therapies 4 (range, 1-8), were enrolled. MM was triple-class refractory in 38% of patients and 53% of patients had high-risk cytogenetics del(17p), t(4;14), t(14;16) and/or gain 1q. Common treatment-related adverse events (all/Grade 3) were thrombocytopenia 72%/47% (G3 and G4), nausea 72%/6%, anaemia 53%/19% and fatigue 53%/9%, all expected and manageable with supportive care and dose modifications. MTD and RP2D were identified as selinexor 80 mg, carfilzomib 56 mg/m2, and dexamethasone 40 mg, all QW. The overall response rate was 78% including 14 (44%) ≥ very good partial responses. Median progression-free survival was 15 months.ConclusionsWeekly XKd is highly effective and well-tolerated. These data support further investigation of XKd in patients with MM.
- Published
- 2022
18. Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain Amyloidosis
- Author
-
Gertz M, Abonour R, Gibbs SN, Finkel M, Landau H, Lentzsch S, Lin G, Mahindra A, Quock T, Rosenbaum C, Rosenzweig M, Sidana S, Tuchman SA, Witteles R, Yermilov I, and Broder MS
- Subjects
consensus ,hematology ,outcomes research ,mayo stage ,cardiac failure ,Medicine (General) ,R5-920 ,Therapeutics. Pharmacology ,RM1-950 - Abstract
Morie Gertz,1,* Rafat Abonour,2,* Sarah N Gibbs,3,* Muriel Finkel,4,* Heather Landau,5,* Suzanne Lentzsch,6,* Grace Lin,7,* Anuj Mahindra,8,* Tiffany Quock,9,* Cara Rosenbaum,10,* Michael Rosenzweig,11,* Surbhi Sidana,12,* Sascha A Tuchman,13,* Ronald Witteles,12,* Irina Yermilov,3,* Michael S Broder3,* 1Department of Medicine, Mayo Clinic, Rochester, MN, USA; 2Department of Medicine, Indiana University School of Medicine; Director, Multiple Myeloma, Waldenstrom’s Disease and Amyloidosis Program, Indianapolis, IN, USA; 3PHAR (Partnership for Health Analytic Research), Beverly Hills, CA, USA; 4Amyloidosis Support Groups Inc, Wood Dale, IL, USA; 5Memorial Sloan-Kettering Cancer Center, New York, NY, USA; 6Multiple Myeloma and Amyloidosis Program, Columbia University Medical Center, New York, NY, USA; 7Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA; 8Malignant Hematology, Scripps Clinic MD Anderson Cancer Center, La Jolla, CA, USA; 9Health Economics and Outcomes Research, Prothena Biosciences Ltd., South San Francisco, CA, USA; 10Department of Medicine, Hematology/Oncology, Weill Cornell Medical College, New York, NY, USA; 11Division of Multiple Myeloma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA; 12Division of Cardiovascular Medicine, Stanford School of Medicine, Palo Alto, CA, USA; 13Division of Hematology, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA*These authors contributed equally to this workCorrespondence: Michael S Broder, PHAR (Partnership for Health Analytic Research), 280 S Beverly Drive, Suite 404, Beverly Hills, CA, 90212, USA, Tel +1 310 858 9555, Email mbroder@pharllc.comPurpose: Patients with diagnosed with systemic light chain (AL) amyloidosis at advanced Mayo stages have greater morbidity and mortality than those diagnosed at non-advanced stages. Estimating service use by severity is difficult because Mayo stage is not available in many secondary databases. We used an expert panel to estimate healthcare utilization among advanced and non-advanced AL amyloidosis patients.Patients and Methods: Using the RAND/UCLA modified Delphi method, expert panelists completed 180 healthcare utilization estimates, consisting of inpatient and outpatient visits, testing, chemotherapy, and procedures by disease severity and organ involvement during two treatment phases (the 1 year after starting first line [1L] therapy and 1 year following treatment [post-1L]). Estimates were also provided for post-1L by hematologic treatment response (complete or very good partial response [CR/VGPR], partial, no response or relapse [PR/NR/R]). Areas of disagreement were discussed during a meeting, after which ratings were completed a second time.Results: During 1L therapy, 55% of advanced patients had ≥ 1 hospitalization and 38% had ≥ 2 admissions. Rates of hematopoietic stem cell transplant (HSCT) in advanced patients were 5%, while pacemaker or implantable cardioverter defibrillator (ICD) placement were 15%. During post-1L therapy, rates of hospitalization in advanced patients remained high (≥ 1 hospitalization: 20-43%, ≥ 2 hospitalizations: 10-20%), and up to 10% of advanced patients had a HSCT. Ten percent of these patients underwent pacemaker/ICD placement.Conclusion: Experts estimated advanced patients, who would not be good candidates for HSCT, would have high rates of hospitalization (traditionally the most expensive type of healthcare utilization) and other health service use. The development of new treatment options that can facilitate organ recovery and improve function may lead to decreased utilization.Keywords: consensus, hematology, outcomes research, mayo stage, cardiac failure
- Published
- 2023
19. Optical coherence tomography angiography for the detection of macular neovascularization—comparison of en face versus cross-sectional view
- Author
-
Siggel, Robert, Spital, Christel, Lentzsch, Anna, and Liakopoulos, Sandra
- Published
- 2023
- Full Text
- View/download PDF
20. The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease
- Author
-
Jing Fu, Shirong Li, Huihui Ma, Jun Yang, Gabriel M. Pagnotti, Lewis M. Brown, Stephen J. Weiss, Markus Y. Mapara, and Suzanne Lentzsch
- Subjects
Science - Abstract
Abstract Multiple myeloma bone disease is characterized by the development of osteolytic bone lesions. Recent work identified matrix metalloproteinase 13 as a myeloma-derived fusogen that induces osteoclast activation independent of its proteolytic activity. We now identify programmed death-1 homolog, PD-1H, as the bona fide MMP-13 receptor on osteoclasts. Silencing PD-1H or using Pd-1h -/- bone marrow cells abrogates the MMP-13-enhanced osteoclast fusion and bone-resorptive activity. Further, PD-1H interacts with the actin cytoskeleton and plays a necessary role in supporting c-Src activation and sealing zone formation. The critical role of PD-1H in myeloma lytic bone lesions was confirmed using a Pd-1h -/- myeloma bone disease mouse model wherein myeloma cells injected into Pd-1h -/- Rag2 -/- results in attenuated bone destruction. Our findings identify a role of PD-1H in bone biology independent of its known immunoregulatory functions and suggest that targeting the MMP-13/PD-1H axis may represent a potential approach for the treatment of myeloma associated osteolysis.
- Published
- 2023
- Full Text
- View/download PDF
21. Correction: COVID-19 Infections and Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
- Author
-
Hultcrantz, Malin, Richter, Joshua, Rosenbaum, Cara, Patel, Dhwani, Smith, Eric, Korde, Neha, Lu, Sydney, Mailankody, Sham, Shah, Urvi, Lesokhin, Alexander, Hassoun, Hani, Tan, Carlyn, Maura, Francesco, Derkach, Andriy, Diamond, Benjamin, Rossi, Adriana, Pearse, Roger, Madduri, Deepu, Chari, Ajai, Kaminetzky, David, Braunstein, Marc, Gordillo, Christian, Reshef, Ran, Taur, Ying, Davies, Faith, Jagannath, Sundar, Niesvizky, Ruben, Lentzsch, Suzanne, Morgan, Gareth, and Landgren, Ola
- Abstract
[This corrects the article DOI: 10.1158/2643-3230.BCD-20-0102.].
- Published
- 2020
22. COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers.
- Author
-
Hultcrantz, Malin, Richter, Joshua, Rosenbaum, Cara, Patel, Dhwani, Smith, Eric, Korde, Neha, Lu, Sydney, Mailankody, Sham, Shah, Urvi, Lesokhin, Alexander, Hassoun, Hani, Tan, Carlyn, Maura, Francesco, Derkach, Andriy, Diamond, Benjamin, Rossi, Adriana, Pearse, Roger, Madduri, Deepu, Chari, Ajai, Kaminetzky, David, Braunstein, Marc, Gordillo, Christian, Reshef, Ran, Taur, Ying, Davies, Faith, Jagannath, Sundar, Niesvizky, Ruben, Lentzsch, Suzanne, Morgan, Gareth, and Landgren, Ola
- Abstract
UNLABELLED: Patients with multiple myeloma have a compromised immune system, due to both the disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID-19. Here, we report outcomes and risk factors for serious disease in patients with multiple myeloma treated at five large academic centers in New York City in the spring of 2020, during which it was a global epicenter of the SARS-CoV-2 pandemic. Of 100 patients with multiple myeloma (male 58%; median age 68) diagnosed with COVID-19, 75 were admitted; of these, 13 patients (17%) were placed on invasive mechanical ventilation, and 22 patients (29%) expired. Of the 25 nonadmitted patients, 4 were asymptomatic. There was a higher risk of adverse outcome (intensive care unit admission, mechanical ventilation, or death) in Hispanics/Latinos (n = 21), OR = 4.7 (95% confidence interval, 1.3-16.7), and African American Blacks (n = 33), OR = 3.5 (1.1-11.5), as compared with White patients (n = 36). Patients who met the adverse combined endpoint had overall higher levels of inflammatory markers and cytokine activation. None of the other studied risk factors were significantly associated (P > 0.05) with adverse outcome: hypertension (n = 56), OR = 2.2 (0.9-5.4); diabetes (n = 18), OR = 0.9 (0.3-2.9); age >65 years (n = 63), OR = 1.8 (0.7-4.6); high-dose melphalan with autologous stem cell transplant
- Published
- 2020
23. The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma
- Author
-
Lindsay Hammons, Aniko Szabo, Abhishek Janardan, Vineel Bhatlapenumarthi, Evanka Annyapu, Binod Dhakal, Samer Al Hadidi, Sabarinath Venniyil Radhakrishnan, Ravi Narra, Divaya Bhutani, Sharmilan Thanendrarajan, Siegfried Janz, Maurizio Zangari, Suzanne Lentzsch, Frits van Rhee, Juan Carlos Rico Crescencio, Anita D’Souza, Rajshekhar Chakraborty, Meera Mohan, and Carolina Schinke
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
There is a paucity of granular data on infection risk with B-cell maturation antigen (BMCA) and GPRC5D bispecific antibodies (bsAb) in relapsed/refractory multiple myeloma (RRMM). The aim of our multi-institutional study was to characterize the incidence, etiologies, and risk factors of infections from the start of therapy to the last follow-up or 90 days after study exit. A total of 66 patients received BCMA bsAb monotherapy, 15 GPRC5D bsAb monotherapy, and 15 GPRC5D bsAb combination therapy with daratumumab and/or pomalidomide. While the infection rate per 100 days was 0.57 for BCMA bsAb, it was 0.62 for GPRC5D bsAb combination and 0.13 for GPRC5D bsAb monotherapy; P=0.05. The proportion of infections that were grade ≥3 was higher in the BCMA bsAb group compared to the GPRC5D groups (58% vs. 36%; P=0.04). Grade 5 events were observed in 8% (n=8) of the patients, all treated with BCMA bsAb. The 9 month cumulative incidence of any grade of infection was similar in the BCMA and GPRC5D-combination groups (57% and 62%) and significantly higher than in the GPRC5D-mono group (16%); P=0.012. The cumulative incidence of grade ≥3 infections was highest in the BCMA group reaching 54% at 18 months; P=0.06. Multivariate analysis showed that BCMA bsAb therapy or GPRC5D combination therapy, history of previous infections, baseline lymphopenia, and baseline hypogammaglobulinemia were significantly associated with a higher risk of grade ≥3 infections. Our results indicate that BCMA bsAb and GPRC5D-combination therapies in RRMM are associated with higher cumulative incidence of infection and grade ≥3 infection compared to GPRC5D bsAb mono.
- Published
- 2023
- Full Text
- View/download PDF
24. S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
- Author
-
Hans C. Lee, Naresh Bumma, Joshua Richter, Madhav Dhodapkar, James E. Hoffman, Attaya Suvannasankha, Jeffrey Zonder, Mansi R. Shah, Suzanne Lentzsch, Joseph J. Maly, Jing Christine Ye, Ka Lung Wu, Michelle Deveaux, Dhruti Chokshi, Anita Boyapati, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn Kroog, Yariv Houvras, and Sundar Jagannath
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
25. P982: EFFICACY AND SAFETY OF 40 MG VS 60 MG OF ONCE WEEKLY SELINEXOR IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)
- Author
-
Darrell White, Muhamed Baljevic, Gary Schiller, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane Van Domelen, Ohad Bentur, and Sumit Madan
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
26. PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
- Author
-
Rajshekhar Chakraborty, Claudia Bellofiore, Marco Basset, Mario Nuvolone, Andrea Foli, Giampaolo Merlini, Giovanni Palladini, Mathew Maurer, Markus Mapara, Divaya Bhutani, Suzanne Lentzsch, and Paolo Milani
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2023
- Full Text
- View/download PDF
27. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials.
- Author
-
Gavriatopoulou, Maria, Chari, Ajai, Chen, Christine, Bahlis, Nizar, Vogl, Dan, Jakubowiak, Andrzej, Dingli, David, Cornell, Robert, Hofmeister, Craig, Siegel, David, Berdeja, Jesus, Reece, Donna, White, Darrell, Lentzsch, Suzanne, Gasparetto, Cristina, Huff, Carol, Jagannath, Sundar, Baz, Rachid, Nooka, Ajay, Richter, Joshua, Abonour, Rafat, Parker, Terri, Yee, Andrew, Moreau, Philippe, Lonial, Sagar, Tuchman, Sascha, Weisel, Katja, Mohty, Mohamad, Choquet, Sylvain, Unger, T, Li, Kai, Chai, Yi, Li, Lingling, Shah, Jatin, Shacham, Sharon, Kauffman, Michael, and Dimopoulos, Meletios
- Subjects
Aged ,Antineoplastic Agents ,Appetite ,Clinical Trials as Topic ,Diarrhea ,Fatigue ,Female ,Humans ,Hydrazines ,Hyponatremia ,Male ,Middle Aged ,Multiple Myeloma ,Nausea ,Thrombocytopenia ,Triazoles - Abstract
Selinexor is an oral, small molecule inhibitor of the nuclear export protein exportin 1 with demonstrated activity in hematologic and solid malignancies. Side effects associated with selinexor include nausea, vomiting, fatigue, diarrhea, decreased appetite, weight loss, thrombocytopenia, neutropenia, and hyponatremia. We reviewed 437 patients with multiple myeloma treated with selinexor and assessed the kinetics of adverse events and impact of supportive care measures. Selinexor reduced both platelets and neutrophils over the first cycle of treatment and reached a nadir between 28 and 42 days. Platelet transfusions and thrombopoietin receptor agonists were effective at treating thrombocytopenia, and granulocyte colony stimulating factors were effective at resolving neutropenia. The onset of gastrointestinal side effects (nausea, vomiting, and diarrhea) was most common during the first 1-2 weeks of treatment. Nausea could be mitigated with 5-HT3 antagonists and either neurokinin 1 receptor antagonists, olanzapine, or cannbainoids. Loperamide and bismuth subsalicylate ameliorated diarrhea. The primary constitutional side effects of fatigue and decreased appetite could be managed with methylphenidate, megestrol, cannabinoids or olanzapine, respectively. Hyponatremia was highly responsive to sodium replacement. Selinexor has well-established adverse effects that mainly occur within the first 8 weeks of treatment, are reversible, and respond to supportive care.
- Published
- 2020
28. Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment
- Author
-
Muhamed Baljevic, Cristina Gasparetto, Gary J. Schiller, Sascha A. Tuchman, Natalie S. Callander, Suzanne Lentzsch, Jorge Monge, Rami Kotb, Nizar J. Bahlis, Darrell White, Christine I. Chen, Heather J. Sutherland, Sumit Madan, Richard LeBlanc, Michael Sebag, Christopher P. Venner, William I. Bensinger, Noa Biran, Andrew DeCastro, Dane R. Van Domelen, Chris Zhang, Jatin J. Shah, Sharon Shacham, Michael G. Kauffman, Ohad S. Bentur, and Brea Lipe
- Subjects
anti‐BCMA ,multiple myeloma ,selinexor ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti‐B‐cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti‐BCMA‐targeted chimeric antigen receptor‐T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA‐antibody‐drug conjugate therapy. We observe that X‐containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients’ prior anti‐BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X‐based regimens following broader anti‐BCMA therapy.
- Published
- 2022
- Full Text
- View/download PDF
29. Flexor tenosynovectomy in carpal tunnel syndrome as a screening tool for early diagnosis of amyloidosis
- Author
-
Bäcker, Henrik C., Galle, Samuel E., Lentzsch, Suzanne, Freibott, Christina E., Shoap, Seth, Strauch, Robert J., and Rosenwasser, Melvin P.
- Published
- 2022
- Full Text
- View/download PDF
30. Dislokation eines STARflo-Glaukomdrainageimplantats mit begleitenden Komplikationen
- Author
-
Schrittenlocher, S., Doulis, A., Koch, K. R., Lappas, A., Altay, L., Lentzsch, A.-M., Cursiefen, C., Bachmann, B., Prokosch-Willing, V., and Dietlein, T.
- Published
- 2022
- Full Text
- View/download PDF
31. We Value Your Privacy ... Now Take Some Cookies: Measuring the GDPR's Impact on Web Privacy
- Author
-
Degeling, Martin, Utz, Christine, Lentzsch, Christopher, Hosseini, Henry, Schaub, Florian, and Holz, Thorsten
- Subjects
Computer Science - Computers and Society - Abstract
The European Union's General Data Protection Regulation (GDPR) went into effect on May 25, 2018. Its privacy regulations apply to any service and company collecting or processing personal data in Europe. Many companies had to adjust their data handling processes, consent forms, and privacy policies to comply with the GDPR's transparency requirements. We monitored this rare event by analyzing the GDPR's impact on popular websites in all 28 member states of the European Union. For each country, we periodically examined its 500 most popular websites - 6,579 in total - for the presence of and updates to their privacy policy. While many websites already had privacy policies, we find that in some countries up to 15.7 % of websites added new privacy policies by May 25, 2018, resulting in 84.5 % of websites having privacy policies. 72.6 % of websites with existing privacy policies updated them close to the date. Most visibly, 62.1 % of websites in Europe now display cookie consent notices, 16 % more than in January 2018. These notices inform users about a site's cookie use and user tracking practices. We categorized all observed cookie consent notices and evaluated 16 common implementations with respect to their technical realization of cookie consent. Our analysis shows that core web security mechanisms such as the same-origin policy pose problems for the implementation of consent according to GDPR rules, and opting out of third-party cookies requires the third party to cooperate. Overall, we conclude that the GDPR is making the web more transparent, but there is still a lack of both functional and usable mechanisms for users to consent to or deny processing of their personal data on the Internet., Comment: Published at NDSS 2019
- Published
- 2018
- Full Text
- View/download PDF
32. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
- Author
-
Shaji Kumar, Lawrence Baizer, Natalie S. Callander, Sergio A. Giralt, Jens Hillengass, Boris Freidlin, Antje Hoering, Paul G. Richardson, Elena I. Schwartz, Anthony Reiman, Suzanne Lentzsch, Philip L. McCarthy, Sundar Jagannath, Andrew J. Yee, Richard F. Little, and Noopur S. Raje
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract A wide variety of new therapeutic options for Multiple Myeloma (MM) have recently become available, extending progression-free and overall survival for patients in meaningful ways. However, these treatments are not curative, and patients eventually relapse, necessitating decisions on the appropriate choice of treatment(s) for the next phase of the disease. Additionally, an important subset of MM patients will prove to be refractory to the majority of the available treatments, requiring selection of effective therapies from the remaining options. Immunomodulatory agents (IMiDs), proteasome inhibitors, monoclonal antibodies, and alkylating agents are the major classes of MM therapies, with several options in each class. Patients who are refractory to one agent in a class may be responsive to a related compound or to a drug from a different class. However, rules for selection of alternative treatments in these situations are somewhat empirical and later phase clinical trials to inform those choices are ongoing. To address these issues the NCI Multiple Myeloma Steering Committee formed a relapsed/refractory working group to review optimal treatment choices, timing, and sequencing and provide recommendations. Additional issues considered include the role of salvage autologous stem cell transplantation, risk stratification, targeted approaches for genetic subsets of MM, appropriate clinical trial endpoints, and promising investigational agents. This report summarizes the deliberations of the working group and suggests potential avenues of research to improve the precision, timing, and durability of treatments for Myeloma.
- Published
- 2022
- Full Text
- View/download PDF
33. IFN-γR/STAT1 signaling in recipient hematopoietic antigen-presenting cells suppresses graft-versus-host disease
- Author
-
Caisheng Lu, Huihui Ma, Liangsong Song, Hui Wang, Lily Wang, Shirong Li, Stephen M. Lagana, Antonia R. Sepulveda, Kasper Hoebe, Samuel S. Pan, Yong-Guang Yang, Suzanne Lentzsch, and Markus Y. Mapara
- Subjects
Immunology ,Transplantation ,Medicine - Abstract
The absence of IFN-γ receptor (IFN-γR) or STAT1 signaling in donor cells has been shown to result in reduced induction of acute graft-versus-host disease (GVHD). In this study, we unexpectedly observed increased activation and expansion of donor lymphocytes in both lymphohematopoietic organs and GVHD target tissues of IFN-γR/STAT1–deficient recipient mice, leading to rapid mortality following the induction of GVHD. LPS-matured, BM-derived Ifngr1–/– Stat1–/– DCs (BMDCs) were more potent allogeneic stimulators and expressed increased levels of MHC II and costimulatory molecules. Similar effects were observed in human antigen-presenting cells (APCs) with knockdown of Stat1 by CRISPR/Cas9 and treatment with a JAK1/2 inhibitor. Furthermore, we demonstrated that the absence of IFN-γR/STAT1 signaling in hematopoietic APCs impaired the presentation of exogenous antigens, while promoting the presentation of endogenous antigens. Thus, the indirect presentation of host antigens to donor lymphocytes was defective in IFN-γR/STAT1–deficient, donor-derived APCs in fully donor chimeric mice. The differential effects of IFN-γR/STAT1 signaling on endogenous and exogenous antigen presentation could provide further insight into the roles of the IFN-γ/STAT1 signaling pathway in the pathogenesis of GVHD, organ rejection, and autoimmune diseases.
- Published
- 2023
- Full Text
- View/download PDF
34. Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma.
- Author
-
Bumma, Naresh, Richter, Joshua, Jagannath, Sundar, Lee, Hans C., Hoffman, James E., Suvannasankha, Attaya, Zonder, Jeffrey A., Shah, Mansi R., Lentzsch, Suzanne, Baz, Rachid, Maly, Joseph J., Namburi, Swathi, Pianko, Matthew J., Ye, Jing Christine, Wu, Ka Lung, Silbermann, Rebecca, Min, Chang-Ki, Vekemans, Marie-Christiane, Munder, Markus, and Byun, Ja Min
- Published
- 2024
- Full Text
- View/download PDF
35. Comparison of swept-source versus spectral-domain optical coherence tomography angiography for detection of macular neovascularization
- Author
-
Lentzsch, Anna, Schöllhorn, Laura, Schnorr, Christel, Siggel, Robert, and Liakopoulos, Sandra
- Published
- 2022
- Full Text
- View/download PDF
36. Gene expression profiling impacts treatment decision making in newly diagnosed multiple myeloma patients in the prospective PROMMIS trial
- Author
-
Noa Biran, Binod Dhakal, Suzanne Lentzsch, David Siegel, Saad Z. Usmani, Adriana Rossi, Cara Rosenbaum, Divaya Bhutani, David H. Vesole, Cesar Rodriguez, Ajay K. Nooka, Frits vanRhee, Lisette Stork‐Sloots, Femke deSnoo, Pritish K. Bhattacharyya, Durga Prasad Dash, Sena Zümrütçü, Martin H. vanVliet, Parameswaran Hari, and Ruben Niesvizky
- Subjects
clinical trials ,gene arrays ,gene expression ,multiple myeloma ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Multiple myeloma (MM) is a heterogeneous hematologic malignancy associated with several risk factors including genetic aberrations which impact disease response and survival. Thorough risk classification is essential to select the best clinical strategy to optimize outcomes. The SKY92 molecular signature classifies patients as standard‐ or high‐risk for progression. The PRospective Observational Multiple Myeloma Impact Study (PROMMIS; NCT02911571) measures impact of SKY92 on risk classification and treatment plan. Newly diagnosed MM patients had bone marrow aspirates analyzed for SKY92. Physicians completed a questionnaire for each patient capturing risk classification, hypothetical treatment plan, and physician confidence in the treatment plan, before and after unblinding SKY92. One hundred forty seven MM patients were enrolled. Before unblinding SKY92, physicians regarded 74 (50%) patients as clinical standard‐risk. After unblinding SKY92, 16 patients were re‐assigned as high‐risk by the physician, and for 15 of them treatment strategy was impacted, resulting in an escalated treatment plan. For the 73 (50%) clinical high‐risk patients, SKY92 indicated 46 patients to be standard‐risk; for 31 of these patients the treatment strategy was impacted consistent with a de‐escalation of risk. Overall, SKY92 impacted treatment decisions in 37% of patients (p
- Published
- 2021
- Full Text
- View/download PDF
37. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
- Author
-
Kumar, Shaji, Baizer, Lawrence, Callander, Natalie S., Giralt, Sergio A., Hillengass, Jens, Freidlin, Boris, Hoering, Antje, Richardson, Paul G., Schwartz, Elena I., Reiman, Anthony, Lentzsch, Suzanne, McCarthy, Philip L., Jagannath, Sundar, Yee, Andrew J., Little, Richard F., and Raje, Noopur S.
- Published
- 2022
- Full Text
- View/download PDF
38. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies
- Author
-
Deng, Changchun, Lipstein, Mark R, Scotto, Luigi, Jirau Serrano, Xavier O, Mangone, Michael A, Li, Shirong, Vendome, Jeremie, Hao, Yun, Xu, Xiaoming, Deng, Shi-Xian, Realubit, Ronald B, Tatonetti, Nicholas P, Karan, Charles, Lentzsch, Suzanne, Fruman, David A, Honig, Barry, Landry, Donald W, and O'Connor, Owen A
- Subjects
Genetics ,Hematology ,Cancer ,Orphan Drug ,Lymphoma ,Rare Diseases ,Biotechnology ,Development of treatments and therapeutic interventions ,5.1 Pharmaceuticals ,Animals ,Antineoplastic Agents ,Casein Kinase 1 epsilon ,Cell Line ,Tumor ,Drug Synergism ,Hematologic Neoplasms ,Humans ,Mice ,Oligopeptides ,Phosphoinositide-3 Kinase Inhibitors ,Protein Biosynthesis ,Protein Kinase Inhibitors ,Proto-Oncogene Proteins c-myc ,Random Allocation ,Xenograft Model Antitumor Assays ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Paediatrics and Reproductive Medicine ,Immunology - Abstract
Phosphoinositide 3-kinase (PI3K) and the proteasome pathway are both involved in activating the mechanistic target of rapamycin (mTOR). Because mTOR signaling is required for initiation of messenger RNA translation, we hypothesized that cotargeting the PI3K and proteasome pathways might synergistically inhibit translation of c-Myc. We found that a novel PI3K δ isoform inhibitor TGR-1202, but not the approved PI3Kδ inhibitor idelalisib, was highly synergistic with the proteasome inhibitor carfilzomib in lymphoma, leukemia, and myeloma cell lines and primary lymphoma and leukemia cells. TGR-1202 and carfilzomib (TC) synergistically inhibited phosphorylation of the eukaryotic translation initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1), leading to suppression of c-Myc translation and silencing of c-Myc-dependent transcription. The synergistic cytotoxicity of TC was rescued by overexpression of eIF4E or c-Myc. TGR-1202, but not other PI3Kδ inhibitors, inhibited casein kinase-1 ε (CK1ε). Targeting CK1ε using a selective chemical inhibitor or short hairpin RNA complements the effects of idelalisib, as a single agent or in combination with carfilzomib, in repressing phosphorylation of 4E-BP1 and the protein level of c-Myc. These results suggest that TGR-1202 is a dual PI3Kδ/CK1ε inhibitor, which may in part explain the clinical activity of TGR-1202 in aggressive lymphoma not found with idelalisib. Targeting CK1ε should become an integral part of therapeutic strategies targeting translation of oncogenes such as c-Myc.
- Published
- 2017
39. Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis
- Author
-
Muchtar, Eli, Wisniowski, Brendan, Geyer, Susan, Palladini, Giovanni, Milani, Paolo, Merlini, Giampaolo, Schönland, Stefan, Veelken, Kaya, Hegenbart, Ute, Leung, Nelson, Dispenzieri, Angela, Kumar, Shaji K., Kastritis, Efstathios, Dimopoulos, Meletios A., Liedtke, Michaela, Ulloa, Patricia, Sanchorawala, Vaishali, Szalat, Raphael, Dooley, Katharine, Landau, Heather, Petrlik, Erica, Lentzsch, Suzanne, Coltoff, Alexander, Bladé, Joan, Cibeira, M. Teresa, Cohen, Oliver, Foard, Darren, Gillmore, Jullian, Lachmann, Helen, Wechalekar, Ashutosh, and Gertz, Morie A.
- Abstract
IMPORTANCE: Kidney light chain (AL) amyloidosis is associated with a risk of progression to kidney replacement therapy (KRT) and death. Several studies have shown that a greater reduction in proteinuria following successful anticlonal therapy is associated with improved outcomes. OBJECTIVE: To validate graded kidney response criteria and their association with kidney and overall survival (OS). DESIGN, SETTING, AND PARTICIPANTS: This retrospective, multicenter cohort was conducted at 10 referral centers for amyloidosis from 2010 to 2015 and included patients with kidney AL amyloidosis that was evaluable for kidney response and who achieved at least hematologic partial response within 12 months of diagnosis. The median follow-up was 69 (54-88) months. Data analysis was conducted in 2023. EXPOSURE: Four kidney response categories based on the reduction in pretreatment 24-hour urine protein (24-hour UP) levels: complete response (kidCR, 24-hour UP ≤200 mg), very good partial response (kidVGPR, >60% reduction in 24-hour UP), partial response (kidPR, 31%-60% reduction), and no response (kidNR, ≤30% reduction). Kidney response was assessed at landmark points (6, 12, and 24 months) and best kidney response. MAIN OUTCOMES AND MEASURES: Cumulative incidence of progression to KRT and OS. RESULTS: Seven-hundred and thirty-two patients (335 women [45.8%]) were included, with a median (IQR) age of 63 (55-69) years. The median (IQR) baseline 24-hour proteinuria and estimated glomerular filtration rate was 5.3 (2.8-8.5) g per 24 hours and 72 (48-92) mL/min/1.73m2, respectively. In a competing-risk analysis, the 5-year cumulative incidence rates of progression to KRT decreased with deeper kidney responses as early as 6 months from therapy initiation (11%, 12%, 2.1%, and 0% for kidNR, kidPR, kidVGPR, and kidCR, respectively; P = .002) and were maintained at 12 months and 24 months and best kidney response. Patients able to achieve kidCR/kidVGPR by 24 months and at best response had significantly better OS compared with kidPR/kidNR. Kidney progression, defined as a 25% or greater decrease in estimated glomerular filtration rate, was associated with cumulative incidence of progression to KRT and OS. CONCLUSIONS AND RELEVANCE: The results of this cohort study suggest that graded kidney response criteria offers clinically and prognostically meaningful information for treating patients with kidney AL amyloidosis. The response criteria potentially inform kidney survival based on the depth of reduction in 24-hour proteinuria levels and demonstrate an OS advantage for those able to achieve kidCR/kidVGPR compared with kidPR/kidNR. Taken together, achievement of at least kidVGPR by 12 months is needed to ultimately improve kidney and patient survival.
- Published
- 2024
- Full Text
- View/download PDF
40. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma
- Author
-
Cristina Gasparetto, Suzanne Lentzsch, Gary Schiller, Natalie Callander, Sascha Tuchman, Christine Chen, Darrell White, Rami Kotb, Heather Sutherland, Michael Sebag, Muhamed Baljevic, William Bensinger, Richard LeBlanc, Chris Venner, Nizar Bahlis, Adriana Rossi, Noa Biran, Heidi Sheehan, Jean‐Richard Saint‐Martin, Dane Van Domelen, Kazuharu Kai, Jatin Shah, Sharon Shacham, Michael Kauffman, and Brea Lipe
- Subjects
Selinexor ,Multiple Myeloma ,Daratumumab ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract We assessed the safety, efficacy, maximum tolerated dose (MTD), and the recommended phase 2 dose (RP2D) of selinexor, a first in class oral selective inhibitor of nuclear export (100 mg once weekly [QW] or 60 mg twice weekly), in combination with daratumumab (16 mg/kg per label) and dexamethasone (40 mg QW) (SDd) in patients with relapsed refractory multiple myeloma (RRMM). Thirty‐four patients (median prior therapies, 3 [range, 2‐10]) were enrolled; MM was refractory to proteasome inhibitor (PI) in 85%, immunomodulatory agent (IMiD) in 76%, both in 74%, and daratumumab in 6% of patients. Two dose‐limiting toxicities (DLTs) were reported in the selinexor 60 mg twice‐weekly cohort with no DLTs in the 100 mg QW cohort, making 100 mg QW the MTD and RP2D. Common treatment‐related adverse events included thrombocytopenia (70.6%), nausea (70.6%), fatigue (61.8%), anemia (61.8%), and neutropenia (50.0%). Overall response rate was 73% and median progression‐free survival 12.5 months in daratumumab‐naïve patients. SDd was well tolerated and its promising efficacy suggests that further study of this PI‐ and IMiD‐free regimen in RRMM patients who had at least one prior line of therapy including a PI and an IMiD but whose disease is naïve to daratumumab is warranted.
- Published
- 2021
- Full Text
- View/download PDF
41. Pre- and Post-Harvest Infection of Pasteurized Pickles with Fungi and Their Pectinolytic Potential to Soften the Product
- Author
-
Anne-Katrin Kersten, Sabrina Scharf, Anna Jendro, Peter Meurer, Carmen Büttner, and Peter Lentzsch
- Subjects
endo- and exo-PG ,texture quality ,firmness and crunchiness ,cucumber ,fungal contamination ,Plant culture ,SB1-1110 - Abstract
Fungi and their enzymes have long been thought to cause the softening of pasteurized gherkins; however, the exact fungal species and timing of contamination are unknown. Ready-to-sell pickle jars and blossoms of growing gherkins were inoculated with DNA-sequenced fungi isolated from rotting gherkins to cause softening at various stages of production. Ready-to-sell gherkins inoculated with Fusarium oxysporum, Fusarium equiseti, Galactomyces geotrichum, Mucor circinelloides, Mucor hiemalis, Mucor fragilis, Plectosphaerella cucumerina, Alternaria sp., and Cladosporium sp. indicated a measurable texture reduction after pasteurization and 6 months of storage at room temperature. No texture changes were observed in gherkins infected during the growth phase. The fungi M. hiemalis, M. fragilis, and G. geotrichum tolerated the acidic-saline (approx. pH 4) environment in the jar for several days, thus the pectinolytic enzymes of these candidates were tested for heat and pH resistance. Although the measured endo-Polygalacturonase (PG) of M. fragilis had its optimum activity at pH < 4, all fungal enzymes were inactivated within 3 min at 80 °C corresponding to the pasteurization heat. Our study shows that conventionally occurring fungi and their enzymes have the potential to induce softening in pickles. Softening by these fungi is unlikely due to post- or pre-harvest contamination without any other influences.
- Published
- 2023
- Full Text
- View/download PDF
42. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
- Author
-
Vikram J. Premkumar, Suzanne Lentzsch, Samuel Pan, Divaya Bhutani, Joshua Richter, Sundar Jagannath, Michaela Liedtke, Arnaud Jaccard, Ashutosh D. Wechalekar, Raymond Comenzo, Vaishali Sanchorawala, Bruno Royer, Michael Rosenzweig, Jason Valent, Stefan Schönland, Rafael Fonseca, Sandy Wong, and Prashant Kapoor
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Venetoclax is efficacious in relapsed/refractory t(11;14) multiple myeloma, thus warranting investigation in light-chain amyloidosis (AL). This retrospective cohort includes 43 patients with previously treated AL, from 14 centers in the US and Europe. Thirty-one patients harbored t(11;14), 11 did not, and one t(11;14) status was unknown. Patients received a venetoclax-containing regimen for at least one 21- or 28-day cycle; the median prior treatments was three. The hematologic response rate for all patients was 68%; 63% achieved VGPR/CR. t(11;14) patients had higher hematologic response (81% vs. 40%) and higher VGPR/CR rate (78% vs. 30%, odds ratio: 0.12, 95% CI 0.02–0.62) than non-t(11;14) patients. For the unsegregated cohort, median progression-free survival (PFS) was 31.0 months and median OS was not reached (NR). For t(11;14), median PFS was NR and for non-t(11;14) median PFS was 6.7 months (HR: 0.14, 95% CI 0.04–0.53). Multivariate analysis incorporating age, sex, prior lines of therapy, and disease stage suggested a risk reduction for progression or death in t(11;14) patients. Median OS was NR for either subgroup. The organ response rate was 38%; most responders harbored t(11;14). Grade 3 or higher adverse events occurred in 19% with 7% due to infections. These promising results require confirmation in a randomized clinical trial.
- Published
- 2021
- Full Text
- View/download PDF
43. Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: subgroup analysis of CASTOR based on cytogenetic risk
- Author
-
Katja Weisel, Andrew Spencer, Suzanne Lentzsch, Hervé Avet-Loiseau, Tomer M. Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay Nooka, Hang Quach, Markus Munder, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Asher A. Chanan-Khan, Noemi Horvath, Marcelo Capra, Meral Beksac, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Pieter Sonneveld, Tineke Casneuf, Nikki DeAngelis, Himal Amin, Jon Ukropec, Rachel Kobos, and Maria-Victoria Mateos
- Subjects
Clinical trials ,Multiple myeloma ,Myeloma therapy ,Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Multiple myeloma (MM) patients with high cytogenetic risk have poor outcomes. In CASTOR, daratumumab plus bortezomib/dexamethasone (D-Vd) prolonged progression-free survival (PFS) versus bortezomib/dexamethasone (Vd) alone and exhibited tolerability in patients with relapsed or refractory MM (RRMM). Methods This subgroup analysis evaluated D-Vd versus Vd in CASTOR based on cytogenetic risk, determined using fluorescence in situ hybridization and/or karyotype testing performed locally. High-risk patients had t(4;14), t(14;16), and/or del17p abnormalities. Minimal residual disease (MRD; 10−5 sensitivity threshold) was assessed via the clonoSEQ® assay V2.0. Of the 498 patients randomized, 40 (16%) in the D-Vd group and 35 (14%) in the Vd group were categorized as high risk. Results After a median follow-up of 40.0 months, D-Vd prolonged median PFS versus Vd in patients with standard (16.6 vs 6.6 months; HR, 0.26; 95% CI, 0.19-0.37; P < 0.0001) and high (12.6 vs 6.2 months; HR, 0.41; 95% CI, 0.21–0.83; P = 0.0106) cytogenetic risk. D-Vd achieved deep responses, including higher rates of MRD negativity and sustained MRD negativity versus Vd, regardless of cytogenetic risk. The safety profile was consistent with the overall population of CASTOR. Conclusion These updated data reinforce the effectiveness and tolerability of daratumumab-based regimens for RRMM, regardless of cytogenetic risk status. Trial registration ClinicalTrials.gov, NCT02136134 . Registered 12 May 2014
- Published
- 2020
- Full Text
- View/download PDF
44. Use of daratumumab in high risk multiple myeloma: A meta‐analysis
- Author
-
Vikram Premkumar, Samuel Pan, Suzanne Lentzsch, and Divaya Bhutani
- Subjects
cytogenetics ,immunotherapy ,multiple myeloma ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Daratumumab is approved for use in newly diagnosed and relapsed/refractory multiple myeloma (MM), however the patients most likely to benefit from its addition to standard anti‐myeloma therapy is unclear. This meta‐analysis included 2340 newly diagnosed MM patients (1982 with standard risk and 358 with high risk cytogenetics) and 673 patients with relapsed/refractory MM (513 with standard risk and 160 with high risk cytogenetics) to assess which cytogenetic subgroups derived PFS benefit from Daratumumab. Studies included were the CASSIOPEIA, MAIA and ALCYONE (for newly diagnosed MM) and the CASTOR and POLLUX trials (for relapsed/refractory MM). Daratumumab's addition led to a clear benefit in standard risk newly diagnosed MM (HR 0.43; 95% CI, 0.35‐0.53; P
- Published
- 2020
- Full Text
- View/download PDF
45. Determination of spider mite abundance in soil of field-grown cucumbers and in plants under predatory mite pressure in invasive infestations using HRM real-time PCR assay.
- Author
-
Anne-Katrin Kersten, Carmen Büttner, and Peter Lentzsch
- Subjects
Medicine ,Science - Abstract
The two spotted spider mite, Tetranychus urticae Koch L. (Acari: Tetranychidae), is a plant pest that can lead to severe economic losses in open field cucumber cultivation. Between 2017 and 2019 we studied the abundance of spider mites in the soil to estimate the potential infestation pressure of soil colonizing spider mites. The spider mites were heterogeneously distributed in small concentrations in the soil. Soil colonizing spider mites did not affect spider mite abundance on plants and reversed. We observed that spider mite migration occurred primarily from the edge of the field adjacent to the weed strip. In 2020 and 2021, we investigated the efficacy of the predatory mite Neoseiulus californicus (McGregor) for suppressing spider mite hotspots in the cropland. We compared untreated spider mite hotspots with N. californicus treated hotspots and showed that a single release of predatory mites could result in a high level of control when spider mite infestation density was initially high. With this study, soil can be ruled out as a habitat for spider mites, and attention to spider mite pest control can be directed to plant infestations. The highly sensitive HRM real-time PCR assay was used for the quantification of the spider mites.
- Published
- 2022
- Full Text
- View/download PDF
46. S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
- Author
-
J. A. Zonder, J. Richter, N. Bumma, J. Brayer, J. E. Hoffman, W. I. Bensinger, K. L. Wu, L. Xu, D. Chokshi, A. Boyapati, D. Cronier, Y. Houvras, K. Rodriguez Lorenc, G. S. Kroog, M. V. Dhodapkar, S. Lentzsch, D. Cooper, and S. Jagannath
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 - Published
- 2022
- Full Text
- View/download PDF
47. Unklare beidseitige Ödeme im papillomakulären Bündel
- Author
-
Lentzsch, Anna M. and Liakopoulos, Sandra
- Published
- 2020
- Full Text
- View/download PDF
48. Aus- und Weiterbildung in seltenen ophthalmologischen Krankheitsbildern am Beispiel hereditärer Netzhautdystrophien
- Author
-
Lentzsch, Anna M.
- Published
- 2020
- Full Text
- View/download PDF
49. Disrupted radial and tibial microarchitecture in patients with monoclonal gammopathy of undetermined significance
- Author
-
Stein, E.M., Dash, A., Bucovsky, M., Agarwal, S., Fu, J., Lentzsch, S., and Shane, E.
- Published
- 2019
- Full Text
- View/download PDF
50. Venetoclax induces deep hematologic remissions in t(11;14) relapsed/refractory AL amyloidosis
- Author
-
Premkumar, Vikram J., Lentzsch, Suzanne, Pan, Samuel, Bhutani, Divaya, Richter, Joshua, Jagannath, Sundar, Liedtke, Michaela, Jaccard, Arnaud, Wechalekar, Ashutosh D., Comenzo, Raymond, Sanchorawala, Vaishali, Royer, Bruno, Rosenzweig, Michael, Valent, Jason, Schönland, Stefan, Fonseca, Rafael, Wong, Sandy, and Kapoor, Prashant
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.